BMC Infectious Diseases (Jun 2010)

Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort

  • Ndèye Guèye,
  • Sow Papa S,
  • Ndèye Kane,
  • Ndiaye Ibrahima,
  • Diouf Assane,
  • Etard Jean-François,
  • De Beaudrap Pierre,
  • Ecochard René,
  • Delaporte Eric

DOI
https://doi.org/10.1186/1471-2334-10-179
Journal volume & issue
Vol. 10, no. 1
p. 179

Abstract

Read online

Abstract Background Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings. This study describes the incidence of AIDS-defining illnesses (ADI) after HAART initiation and analyzes their risk factors in a low-resource setting. A focus was put on CD4 cell counts and viral load measurements. Methods 404 HIV-1-infected Senegalese adult patients were enrolled in a prospective observational cohort and data censored as of April 2008. A Poisson regression was used to model the incidence of ADIs over two periods and to assess its association with baseline variables, current CD4, current viral load, CD4 response, and virological response. Results ADI incidence declined from 20.5 ADIs per 100 person-years, 95% CI = [16.3;25.8] during the first year to 4.3, 95% CI = [2.3;8.1] during the fourth year but increased afterwards. Before 42 months, the decrease was greater in patients with clinical stage CDC-C at baseline and with a viral load remaining below 1000 cp/mL but was uniform across CD4 strata (p = 0.1). After 42 months, 293 patients were still at risk. The current CD4 and viral load were associated with ADI incidence (decrease of 21% per 50 CD4/mm3 and of 61% for patients with a viral load Conclusions During the first four years, a uniform decline of ADI incidence was observed even in patients with low CD4-cell counts at HAART initiation as long as the viral load remained undetectable. An increase was noted later in patients with immunologic and virological failures but also in patients with only virological failure.